About Us – Biotechpharma


Posted On Sep 14 2016 by

#biotech pharma

#

Partners H2020

Biotechpharma is looking for partnership for the upcoming EU Framework Programme for Research and Innovation “Horizon 2020”. We are eager to join a new Horizon 2020 project as a partner organization, which expertise lies in early and late stage drug development and cGMP-compliant manufacturing of biopharmaceuticals for pre-clinical and Phase I-III clinical trials.

Horizon 2020 is the biggest research and innovation programme in the EU aimed at securing Europe’s global competitiveness. H2020 is running from 2014 to 2020 with a budget of nearly €80 billion.

Biotechpharma would like to join an international H2020 consortium in the field of biotechnology or pharmacy. There are several calls that align with our interests, however, other topics would be considered as well:

  • H2020-NMBP-2016-2017: nanotechnologies, advanced materials, biotechnology and production
  • H2020-SC1-2016-2017: personalised medicine

Biotechpharma could provide various contract Manufacturing and R D services: development of protein manufacturing technology, scale-up, material supply for clinical trials and protein functional and structural research. We have extensive experience in Biosimilar protein development, including monoclonal antibodies, as well as manufacturing of novel drug products, such as interferon alpha molecules and cytokines. We have capacities and capabilities to perform formulation development for both drug substance and drug product. Final drug product can be manufactured in lyophilized form or solution in vials or in pre-filled syringes, which can be labelled and supplied to clinical trials. Finally, we could also provide necessary QC testing services, including analytical methods development, analytical methods transfer or analytical methods implementation following pharmacopoeia. cGMP manufacturing of Master and Working Cell Banks (MCB/WCB) is another service offered by the company. Characterization/testing of MCB/WCB is performed in accordance with the following regulatory guidelines: ICH Q5B, Q5D, Q5A, Q6B, Q7.

Having recently received an approval to undertake one H2020 project, we are eager to join another H2020 project as a partner. Should there be an opportunity to collaborate, please do not hesitate to contact us. We would be glad to work on a new project together.

Last Updated on: September 14th, 2016 at 2:06 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *